abstract |
Provided are a method for determining prognosis of endometrial cancer, a method for determining endometrial cancer patient compatible to preservation therapy, and a method for determining risk of endometrial cancer. The methods comprise detecting DNA methylation level at a target CpG site in a genomic DNA derived from an endometrial cell, endometrial cancer cell or tissue containing the cell. Prognosis of endometrial cancer, compatibility to preservation therapy, or risk of endometrial cancer of a subject is determined on the basis of the detected DNA methylation level. |